TNFRSF8 and lymphoma: Her2/neu-positive breast cancers react to targeted therapy with trastuzumab [163], whereas CD20- or CD30-positive lymphomas can be treated with the humanized monoclonal antibodies rituximab [164] and brentuximab [165], respectively.